Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage

Inflammation in the brain has increasingly been recognized to play an important role in the pathogenesis of several neurodegenerative disorders, including Parkinson's disease (PD). Progress in the search for effective therapeutic strategies that can halt this degenerative process remains limited. We previously showed that micromolar concentrations of dextromethorphan (DM), a major ingredient of widely used antitussive remedies, reduced the inflammation‐mediated degeneration of dopaminergic neurons through the inhibition of microglial activation. In this study, we report that femto‐ and micromolar concentrations of DM (both pre‐ and post‐treatment) showed equal efficacy in protecting lipopolysaccharide (LPS)‐induced dopaminergic neuron death in midbrain neuron‐glia cultures. Both concentrations of DM decreased LPS‐induced release of nitric oxide, tumor necrosis factor‐α, prostaglandin E2 and superoxide from microglia in comparable degrees. The important role of superoxide was demonstrated by DM's failure to show a neuroprotective effect in neuron‐glia cultures from NADPH oxidase‐deficient mice. These results suggest that the neuroprotective effect elicited by femtomolar concentrations of DM is mediated through the inhibition of LPS‐induced proinflammatory factors, especially superoxide. These findings suggest a novel therapeutic concept of using “ultra‐low” drug concentrations for the intervention of inflammation‐related neurodegenerative diseases.—Li, G., Cui, G., Tzeng, N.‐S., Wei, S.‐J., Wang, T., Block, M. L., Hong, J.‐S. Femtomolar concentrations of dextromethorphan protect mesencephalic dopaminergic neurons from inflammatory damage. FASEB J. 19, 489–496 (2005)

[1]  I. Gozes,et al.  NAP, a Femtomolar-Acting Peptide, Protects the Brain Against Ischemic Injury by Reducing Apoptotic Death , 2002, Stroke.

[2]  P. Rameshwar,et al.  Stimulation of IL-2 production in murine lymphocytes by substance P and related tachykinins. , 1993, Journal of immunology.

[3]  B. Liu,et al.  Dextromethorphan Protects Dopaminergic Neurons against Inflammation-Mediated Degeneration through Inhibition of Microglial Activation , 2003, Journal of Pharmacology and Experimental Therapeutics.

[4]  G. Steinberg,et al.  Dextromethorphan reduces neocortical ischemic neuronal damage in vivo , 1988, Brain Research.

[5]  D. Dickson,et al.  Microglia and cytokines in neurological disease, with special reference to AIDS and Alzheimer's disease , 1993, Glia.

[6]  B. Liu,et al.  Primary rat mesencephalic neuron-glia, neuron-enriched, microglia-enriched, and astroglia-enriched cultures. , 2003, Methods in molecular medicine.

[7]  D. Choi,et al.  Morphinans attenuate cortical neuronal injury induced by glucose deprivation in vitro , 1988, Brain Research.

[8]  Bin Liu,et al.  NADPH Oxidase Mediates Lipopolysaccharide-induced Neurotoxicity and Proinflammatory Gene Expression in Activated Microglia* , 2004, Journal of Biological Chemistry.

[9]  Bin Liu,et al.  Microglia enhance β‐amyloid peptide‐induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species , 2002 .

[10]  Bin Liu,et al.  Microglial activation‐mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease , 2002, Journal of neurochemistry.

[11]  Bin Liu,et al.  Microglia enhance beta-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. , 2002, Journal of neurochemistry.

[12]  L. Sazanov,et al.  Inhibition of the respiratory burst in mouse macrophages by ultra‐low doses of an opioid peptide is consistent with a possible adaptation mechanism , 1994, FEBS letters.

[13]  Teruo Hayashi,et al.  Antiapoptotic and cytotoxic properties of delta opioid peptide [D‐Ala2,D‐Leu5]enkephalin in PC12 cells , 2002, Synapse.

[14]  P. Mcgeer,et al.  Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains , 1988, Neurology.

[15]  D. Shibata,et al.  Dextromethorphan protects against cerebral injury following transient focal ischemia in rabbits. , 1988, Stroke.

[16]  S. Tsunawaki,et al.  Mutation at Histidine 338 of gp91 phox Depletes FAD and Affects Expression of Cytochrome b 558 of the Human NADPH Oxidase* , 1998, The Journal of Biological Chemistry.

[17]  X. C. Lu,et al.  Dextromethorphan protects against cerebral injury following transient, but not permanent, focal ischemia in rats. , 1997, Life sciences.

[18]  Bin Liu,et al.  Reduction by naloxone of lipopolysaccharide-induced neurotoxicity in mouse cortical neuron–glia co-cultures , 2000, Neuroscience.

[19]  D. Prince,et al.  Dextromethorphan protects against cerebral infarction in a rat model of hypoxia-ischemia , 1988, Neuroscience Letters.

[20]  K. Shen,et al.  Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia , 2001, Brain Research.

[21]  C. Ong,et al.  Role of intracellular thiol depletion, mitochondrial dysfunction and reactive oxygen species in Salvia miltiorrhiza-induced apoptosis in human hepatoma HepG2 cells. , 2001, Life sciences.

[22]  D. Giulian.  Microglia and the immune pathology of Alzheimer disease. , 1999, American journal of human genetics.

[23]  B. Liu,et al.  Inhibition by Naloxone Stereoisomers of β-Amyloid Peptide (1–42)-induced Superoxide Production in Microglia and Degeneration of Cortical and Mesencephalic Neurons , 2002, Journal of Pharmacology and Experimental Therapeutics.

[24]  M. Li,et al.  Delta-opioid suppression of human immunodeficiency virus-1 expression in T cells (Jurkat). , 1998, Biochemical pharmacology.

[25]  J. Zweier,et al.  Vascular NAD(P)H oxidase is distinct from the phagocytic enzyme and modulates vascular reactivity control. , 2001, American journal of physiology. Heart and circulatory physiology.

[26]  P. Mcgeer,et al.  The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases , 1995, Brain Research Reviews.

[27]  Y. Hosobuchi,et al.  Dynorphin(1–13) improves survival in cats with focal cerebral ischaemia , 1984, Nature.

[28]  S. Gatley,et al.  The effects of diphenyleneiodonium on mitochondrial reactions. Relation of binding of diphenylene[125I]iodonium to mitochondria to the extent of inhibition of oxygen uptake. , 1976, The Biochemical journal.

[29]  Bin Liu,et al.  Role of Microglia in Inflammation-Mediated Neurodegenerative Diseases: Mechanisms and Strategies for Therapeutic Intervention , 2003, Journal of Pharmacology and Experimental Therapeutics.

[30]  T. Peng,et al.  Mitochondrial dysfunction in Parkinson's disease. , 1999, Biochemical Society symposium.

[31]  R. Mohney,et al.  Regional Difference in Susceptibility to Lipopolysaccharide-Induced Neurotoxicity in the Rat Brain: Role of Microglia , 2000, The Journal of Neuroscience.

[32]  Sim Mk,et al.  Endothelium-dependent response of the rabbit aorta to femtomolar concentrations of angiotensin II. , 1991 .

[33]  S. Yang,et al.  Femtomolar concentrations of dynorphins protect rat mesencephalic dopaminergic neurons against inflammatory damage. , 2001, The Journal of pharmacology and experimental therapeutics.

[34]  Jau-Shyong Hong,et al.  Synergistic neurotoxic effects of combined treatments with cytokines in murine primary mixed neuron/glia cultures , 1998, Journal of Neuroimmunology.

[35]  D. Reglodi,et al.  Delayed systemic administration of PACAP38 is neuroprotective in transient middle cerebral artery occlusion in the rat. , 2000, Stroke.

[36]  P. Jenner,et al.  Oxidative stress in Parkinson's disease and other neurodegenerative disorders. , 1996, Pathologie-biologie.

[37]  X. C. Lu,et al.  Neuroprotection (focal ischemia) and neurotoxicity (electroencephalographic) studies in rats with AHN649, a 3-amino analog of dextromethorphan and low-affinity N-methyl-D-aspartate antagonist. , 1999, The Journal of pharmacology and experimental therapeutics.